Value of two-cycle docetaxel, cisplatin, and 5-fluorouracil induction chemotherapy in hypopharyngeal carcinoma

Abstract

Various studies have investigated laryngeal function and survival after induction chemotherapy in hypopharyngeal carcinoma, but potential factors to help predict response rates after induction chemotherapy remain unknown. This retro- spective study evaluated which factors are related to an ineffective response to two-cycle docetaxel, cisplatin, and 5-fluoro- uracil (TPF) induction chemotherapy in hypopharyngeal carcinoma to determine potential candidates for this treatment in clinical practice. From Jan 2005 to Dec 2015, 81 patients diagnosed with hypopharyngeal squamous cell carcinoma based on a pathological examination were analyzed. They were administered two-cycle TPF induction chemotherapy, and magnetic resonance imaging was performed before and after induction chemotherapy. The mean survival time was 5.7 years (95% confidence interval, 5.1-6.2 years). The 1, 3, 5 and 6-year survival rates were 98.8%, 80.1%, 64.5%, and 54.2%, respectively. TPF induction chemotherapy was well tolerated; the main adverse effects resolved with symptomatic treatment. A response to TPF induction chemotherapy was associated with lymph node size, tumor grade, invasion region, T stage, and primary tumor. The following issues were significantly associated with an increasing non-response rate to two-cycle induction chemotherapy: increasing lymph node size, moderately differentiated squamous cell carcinoma, invasion of the esophagus along with the thyroid cartilage, and primary tumor in the piriform sinus. Lymph nodes of ≥2.15 cm, moderately differenti- ated tumor grade, or thyroid cartilage invasion were the best cutoff values for patients who did not respond to induction chemotherapy. However, the initial cancer site, cancer stage, and degree of cancer differentiation were not closely related to the efficacy of induction chemotherapy.

RETRACTED: Combination of Tanshinone IIA and Cisplatin Inhibits Esophageal Cancer by Downregulating NF-κB/COX-2/VEGF Pathway

“…The compound ID (CID) of DDP in PubChem Compound is 441203 ( Figure 1B). It has been extensively utilized to cure different types of neoplasms, including head and neck (9,10), lung (11,12), ovarian (13,14), breast (15,16), brain (17,18), kidney (19,20), and esophagus cancers (21)(22)(23). In general, DDP and other platinum-based compounds are considered to be cytotoxic drugs, which can induce apoptosis of cancer cells (24).…”

A Nomogram for Pretreatment Prediction of Response to Induction Chemotherapy in Locally Advanced Hypopharyngeal Carcinoma

“…Older age, higher HGB, lower T-stage, and lower PLT are associated with a better response to IC. Luo et al demonstrate that a response to IC is associated with lymph node size, tumor grade, invasion region, T-stage, and primary tumor site (24). Previous studies show that histological grade is correlated with chemotherapy response (25)(26)(27).…”

Synergistic or Additive Pharmacological Interactions between Magnoflorine and Cisplatin in Human Cancer Cells of Different Histological Origin

“…Cis-diamminedichloroplatinum (II) (cisplatin, CDDP), due to its broad spectrum of clinical activity and high efficacy, is one of the most extensively used chemotherapeutic drug and anticancer agent for treatment of numerous solid tumors [1][2][3], including testicular cancer [4], ovarian cancer [5], breast cancer [6], cervical cancer [7], non-small cell lung cancer [8], head and neck cancer [9], bladder cancer [10] and others [1,3,11]. Anticancer activity of CDDP has also been demonstrated when it is used in combination with other types of anticancer therapy, including radiotherapy [12], chemotherapy [13] or immunotherapy [3,14]. Unfortunately, the clinical use of CDDP has been largely limited due to its serious severe side effects including nephrotoxicity [15,16], ototoxicity [15], neurotoxicity [17], cardiotoxicity [18], gastrointestinal toxicity [19], hepatotoxicity [16], hematological toxicity [20].…”